Drug Trial Radar · NCT03441581
Eluxadoline Bile Acid Malabsorption (BAM) Study
Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 23, 2018
Primary completion
Apr 28, 2020
Study completion Apr 28, 2020
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
Conditions
- Irritable Bowel Syndrome With Diarrhea
Interventions
EluxadolineDrug
Eluxadoline 100 mg oral tablets BID with food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment PeriodTime frame: Baseline (Day 1) to Week 4
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline (Day 1) to Week 4
- Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory TestsTime frame: Baseline (Day 1) to Week 4
- Number of Participants Who Experienced Potentially Clinically Significant Change in Vital SignsTime frame: Baseline (Day 1) to Week 4
- Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical ExamTime frame: Baseline (Day 1) to Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.